Vertex Stock May See Further Appreciation on Approval, Launch of Povetacicept, RBC Says
Goldman Sachs Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $725
Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $660
Loading...